US is developing mrna-bird flu vaccine – FT

According to Financial Times, the US government is developing mrna-based bird flu vaccine. According to news, the government is having funding talks with Moderna and Pfizer and outcome is expected in June.

The H5N1 outbreak in the US agriculture is increasing the need to speed up the bird flu vaccine stockpile and its manufacturing processes. The current vaccines are seen effective but in case of a pandemic the vaccine manufacturing is too time consuming.

According to CDC, the bird flu cases in the US has been detected in poultry farms in 48 states and dairy cow in nine states. Three dairy workers were affected in recent months.

Pfizer sales 14,9 billion dollars in Q1 – raises full year EPS (updated)

The US pharma company Pfizer said on Wednesday its Q1 revenue decreased 18% to 14,9 billion dollars due to the decline in Covid-medicines.

According to the report, Paxlovid sales were down 50% to 2035 million dollars from year ago. Corminaty sales were only 354 million dollars compared to 3,1 billion dollars year ago.

The company said its R&D expenses were 2493 million dollars compared to 2505 million dollars  year ago.

Pfizer says it is reaffirming  the full year revenue guidance to 58,5 – 61,5 billion dollars but raising the full-year EPS to 2,15 – 2,35 dollars per share.

Pfizer stated in the release that it is on track to get at least 4 billion dollars in net cost savings by the end of this year.

Pfizer’s stock closed up 6,09% to 27,18 dollars in New York trading.

Pfizer Q4 2023 revenue 14,2 billion dollars – reaffirms the full year 2024 guidance

The US pharma company Pfizer reported their earnings figures today. According to release, the full year 2023 revenues were 58,5 billion dollars last year and EPS 0,37 dollars, down 93%. Pfizer said the decline in Covid-drugs, Corminaty and Paxlovid revenues were down 41%.

Pfizer said it is on track to delivere 4 billion dollars annual net cost savings by the end of this year.

The Q4 2023 revenues were 14,2 billion dollars and loss EPS was 0,60 dollars.

The company also says it is reaffirming the full year 2024 guidance of revenues between 58,5 -61,5 billion dollars and EPS between 2,05 -2,25 dollars.

Pfizer: Full year 2024 revenue range 58,5-61,5 billion dollars (updated)

The US pharma company Pfizer has today published its full year 2024 outlook estimates. According to company the revenue is expected to be in range of 58,5 billion dollars to 61,5 billion dollars. It includes expected Seagen acquisition.

Pfizer is also expecting about 8 billion dollars revenues from Covid-drugs Comirnaty and Paxlovid.

The new acquisition Seagen is expected to contribute about 3,1 billion dollars of revenues.

The full year operational revenue growth would be 8-10 % exluding Covid drugs. And the growth would be 3-5% excluding both Seagen, Comirnaty and Paxlovid revenues.

The next year EPS would be between 2,05 – 2,25 dollars, including Seagen. R&D expenses are estimated to be 11,9-12,9 billion dollars.

The cost realignment program is expected to deliver annual net savings at least 4 billion dollars.

-Pfizer’s product portfolio remains strong. In 2024 Comirnaty and Paxlovid are expected to deliver combined revenues of 8 billion dollars, the company CEO Albert Bourla said in the release.

– In addition we expect our cost realignment program to deliver savings of at least 4 billion dollars by the end of 2024, which puts us on a path to potentially regain our pre-pandemic operating msargins, he said.

– We look forward to joining forces with Seagen and using our combined strenghts to bring us ever closer to delivering long promised cures for certain cancers, he concluded.

Pfizer announces topline Phase 2b results of oral GLP, for adults with obesity

The US pharma company Pfizer announced today its topline Phase 2b results from GLP for adults with obesity.

The danuglipron demonstrated weight reductions ranging from 8- 13% at 32 weeks and 5-9,5% at 26 weeks.

According to Pfizer this oral medicine is targeted to adults with obesity and without type 2 diabetes.

– We believe an improved once-daily formulation danuglipron could play an important role in the obesity treatment paradigm, the chief scientific officer Mikael Dolsten in Pfizer R&D.

Pfizer revenues 13,2 billion dollars in Q3 – reaffirms full year quidance

The US pharma company Pfizer (PFE) said last week that its Q3 revenue were 13,2 billion dollars and reaffirmed its full year quidance after the Covid-product profit warning in October.

Pfizer expects its full year revenue to be between 58-61 billion dollars and EPS between 1,45-1,65 dollars. The company also announced a cost saving plan of 3,5 billion dollars in October after the Covid-products decline. The sales of Paxlovid and Comirnaty decreased by 9,3 billion dollars.

The company and Biontech announced positive Phase1/2 topline results from combined Covid & influenza mrna-vaccine in October. Pfizer’s R&D expenses were 2,71 billion dollars during the quarter compared to 2,69 billion dollars year earlier.

– We are encouraged by the strong performance of Pfizer’s non-Covid products in the third quarter of 2023 including significant contributions from new launches and robust year over year growth of several key in-line brands, the company CEO Albert Bourla said in the release.

Pfizer stock closed up 3,82% for the week to 31,26 dollars on Friday.

During a month’s period the company stock has declined by 6,15%.

Biontech and Moderna to report their Covid-outlook in Q3 reports

The profitwarning from the US pharma company Pfizer last Friday triggered the pharma sector on Monday trading.

Biontech stock closed down 6,38% to 96,97 dollars and Moderna’s stock decreased 6,47% to 91,94 dollars in Nasdaq trading in New York on Monday.

Moderna said it will keep its forecast of Covid-sales for this year the same and that the Q3 report on November 2 will highlight the outlook more.

The German biotech company Biontech said it is evaluating the impact of Pfizer’s new sales estimate. The company estimated that the write-offs could mean half of the 0,9 billion dollars write-offs in Q3. Biontech is to report the Q3 in November 6.

Pfizer reported the Covid- products writeoffs on Friday and lowered the full year revenue and earnings quidance as well. The stock recovered on Monday and closed up 3,56% to 33,27 dollars after the news that the company is planning also a cost reduction program of 3,5 billion dollars.

Pfizer updates Covid sales and reduces full year quidance

The US pharma company Pfizer said on Friday that it has reduced the Covid product sales estimates for this year and reduced the full year quidance. The new full year revenue is now 58-61 billion dollars when it was earlier 67-70 billion dollars. The EPS estimate is now 1,45-1,65 dollars when it was earlier 3,25-3,45 dollars.

According to Pfizer, it has reduced the Comirnaty revenue quidance by approximately 2 billion dollars and for Paxlovid about 7 billion dollars. The decline is about 9 billion dollars in the Covid-products.

The company informed cost cutting program of about 3,5 billion dollars.

Pfizer said also that it has reached an agreement with the US government to provide Paxlovid free of charge for federally insured patients through 2024 as the government returns about 7,9 million Paxlovid treatment courses by the year end.

Pfizer will also provide the US goverment with one million treatment for a strategic national stockpile and the company continues to commersialise the product further.

According to company CEO Albert Bourla, the non-covid portfolio remains strong and the company continues to expect these products to achieve year-over year operational revenue growth in the range of 6-8% in 2023.

US FDA approves Pfizer’s treatment for lung cancer

The US FDA has approved the Pfizer’s Braftovi and Mektoni for adults to be used as personalized treatment for non-small cell lung cancer.

– Today’s approval builds on our longstanding commitment to deliver innovative, personalized medicines to patients with lung cancer, the company EVP Chris Boshoff said in the release.

Pfizer has the exclusive rights to the commercialization of the products for ex in Americas. Pierre Fabre has the rights in Europe and Ono Pharmaceuticals in Japan and South Korea.

Pfizer to get committee recommendation for infant RSV vaccine

The US pharma company Pfizer reported on Friday that the CDC Advisory committee has recommended the company’s RSV vaccine for infants. Earlier Pfizer got the marketing approval for RSV vaccine for older adults.

The company says the Abrysvo recommendation for pregnant persons 32 through 36 weeks gestation would help to protect the baby from RSV from birth through the first six months of life.

Pfizer says it is the only company with an RSV vaccine to help older adults as well as infants. This recommendation will be official once it is reviewed and adopted by the CDC.

This is also the first time when people can have access to the RSV vaccine, Covid-19 vaccine and flu vaccine.